Localised Scleroderma (Morphea) – A Comprehensive Guide
Overview
Localised scleroderma, also known as morphea, is a rare autoimmune disease that causes hard, discoloured patches of skin (and sometimes deeper tissues) due to excessive collagen deposition. Unlike systemic scleroderma, morphea generally does not affect internal organs, but it can cause significant cosmetic concerns, functional limitations, and emotional distress.
Who it affects
- Most commonly diagnosed in children and young adults (average onset 10–30 years).
- Women are about twice as likely to develop morphea as men.
- All ethnic groups can be affected, but rates appear slightly higher in Caucasian populations.
Prevalence
Population‑based studies estimate an incidence of roughly 0.4–2 cases per 100,000 people per year, with a prevalence of 2–4 per 100,000.[1] Because it is often mild and may resolve spontaneously, true numbers could be higher.
Symptoms
Morphea presents with a spectrum of skin changes that evolve over time. The main categories are:
Cutaneous signs
- Indurated plaques – firm, raised patches that may be ivory‑white, pink, or purplish. Borders are often well defined.
- Pigmentary changes – hyperpigmentation (darker) or hypopigmentation (lighter) around the lesion.
- Atrophy – thinning of the skin over the plaque, sometimes giving a “shiny” appearance.
- Linear streaks – narrow bands that follow the lines of Blaschko (embryologic skin lines), often on limbs or the scalp.
- “Mouth‑like” borders – especially in deep morphea, edges may look ragged or ulcerated.
Deep tissue involvement
- Subcutaneous thickening, leading to a firm, rope‑like feel under the skin.
- Muscle or fascia involvement causing reduced range of motion, especially when lesions cross joints.
- Joint contractures or limited mobility in severe linear or deep morphea.
Other possible features
- Hair loss (alopecia) – particularly over scalp plaques.
- Calcinosis – calcium deposits under the skin, appearing as hard nodules.
- Neurologic symptoms – rare, but can include seizures or headaches when lesions involve the brain or meninges (mostly in “en coup de sabre” facial morphea).
Causes and Risk Factors
While the exact trigger remains unknown, morphea is believed to arise from a combination of genetic susceptibility, immune dysregulation, and environmental influences.
Potential causes
- Autoimmune mechanisms – abnormal T‑cell activation and cytokine release (e.g., TGF‑β, IL‑4) promote excess collagen production.[2]
- Genetic predisposition – certain HLA alleles (HLA‑DRB1*04) appear more frequently in patients.
- Trauma or infection – a skin injury, radiation, or viral infection may act as a “second hit” initiating the disease in predisposed individuals.
- Medication‑related – rare cases reported after exposure to bleomycin, interferon‑α, or chemotherapy agents.
Risk factors
- Family history of autoimmune disease (e.g., rheumatoid arthritis, lupus).
- Previous cutaneous injury or radiation therapy.
- Certain infections (e.g., Borrelia burgdorferi) – evidence remains controversial.
- Being female and aged 10‑30 years (peak incidence).
Diagnosis
Diagnosis is primarily clinical but often requires supportive testing to confirm the type and depth of involvement and to rule out systemic disease.
Clinical examination
- Visual inspection of skin lesions (size, shape, colour, depth).
- Palpation to assess hardness and induration.
- Measurement of joint range of motion when lesions cross joints.
Skin biopsy
Full‑thickness punch or excisional biopsy demonstrates thickened collagen bundles, loss of adnexal structures, and an interface dermatitis. Histology helps differentiate morphea from other sclerosing dermatoses.
Imaging
- Ultrasound – evaluates depth of dermal and subdermal involvement.
- Magnetic resonance imaging (MRI) – especially for deep or linear lesions near joints or the central nervous system.
- Dual‑energy X‑ray absorptiometry (DEXA) – sometimes used to assess bone involvement in severe cases.
Laboratory tests
- Autoantibody panel (ANA, anti‑centromere, anti‑Scl‑70) – usually negative in isolated morphea but performed to exclude systemic sclerosis.
- Inflammatory markers (ESR, CRP) – may be modestly elevated during active disease.
- Complete blood count & metabolic panel – baseline before initiating systemic therapy.
Assessment of disease activity
Tools such as the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) quantify skin thickness and activity, guiding treatment decisions.[3]
Treatment Options
Therapy aims to halt inflammation, prevent progression, and improve cosmetic appearance. Treatment selection depends on lesion type (superficial vs. deep), location, and disease activity.
Topical therapies
- High‑potency corticosteroids (e.g., clobetasol propionate 0.05%) – first‑line for recent, active plaques; applied 2‑3 times daily for 4‑6 weeks.
- Topical tacrolimus (0.1% ointment) – useful for facial lesions or where steroids cause atrophy.
- Vitamin D analogues (calcipotriene) – may aid in early inflammatory lesions.
Phototherapy
- UVA‑1 (340–400 nm) – penetrates deep dermis; typical regimen: 20–40 J/cm² three times weekly for 6–12 weeks. Effective for moderate‑depth morphea.
- PUVA (psoralen + UVA) – alternative when UVA‑1 is unavailable.
Systemic medications
- Methotrexate (0.5–1 mg/kg weekly, max 25 mg) – the most studied systemic agent; often combined with low‑dose oral prednisone (≤0.5 mg/kg) for the first 3–6 months.[4]
- Mycophenolate mofetil (1–1.5 g twice daily) – an alternative for methotrexate‑intolerant patients.
- Systemic corticosteroids – short courses (≤4 weeks) for rapidly progressive disease.
- Biologic agents – limited data, but abatacept and tocilizumab have shown benefit in refractory cases.
Procedural interventions
- Intralesional corticosteroid injections – triamcinolone acetonide (10–20 mg/mL) into deep plaques.
- Laser therapy – pulsed‑dye laser for erythematous lesions; fractional CO₂ laser can improve texture after disease stabilization.
- Physical therapy – essential for linear lesions crossing joints to preserve range of motion.
Lifestyle & supportive measures
- Moisturize daily with fragrance‑free emollients to reduce itching.
- Sun protection (SPF 30+) – UV exposure may exacerbate inflammation.
- Balanced diet rich in antioxidants (vitamins C, E) – supports skin health.
- Smoking cessation – smoking impairs wound healing and may worsen fibrosis.
Living with Localised Scleroderma (Morphea)
While morphea is not life‑threatening, it can affect daily functioning and emotional well‑being. Practical strategies include:
- Regular skin checks – monitor lesions for changes in size, colour, or texture.
- Physical therapy – schedule sessions early if lesions involve joints; home stretching programs help maintain mobility.
- Psychological support – counselling or support groups (e.g., Scleroderma Foundation) can address body‑image concerns.
- Cosmetic options – medical‑grade silicone gels, camouflaging makeup, or laser resurfacing after disease inactivity.
- School & work accommodations – inform teachers or employers about the condition; request flexible scheduling for appointments or physical‑therapy breaks.
- Medication adherence – set reminders, use pill organisers, and keep a symptom diary to discuss with your clinician.
Prevention
Because the exact cause is unclear, primary prevention is limited. However, risk reduction strategies include:
- Prompt treatment of skin injuries, infections, or radiation burns.
- Avoiding unnecessary skin trauma (e.g., aggressive scratching).
- Maintaining good overall immune health – balanced diet, regular exercise, adequate sleep.
- Screening for and managing other autoimmune conditions early.
Complications
If morphea is left untreated or inadequately controlled, several complications may arise:
- Joint contractures – especially with linear lesions over elbows, knees, or fingers, leading to functional disability.
- Growth disturbances – in children, deep lesions over growing bones can cause limb length discrepancy.
- Cosmetic disfigurement – permanent hypo‑ or hyper‑pigmentation and atrophy may cause psychosocial stress.
- Calcinosis – painful calcium deposits that can ulcerate.
- Neurologic sequelae – rare but possible with facial “en coup de sabre” lesions (seizures, visual field defects).
- Secondary infection – ulcerated plaques can become colonised with bacteria or fungi.
When to Seek Emergency Care
- Sudden, severe swelling or pain in a morphea‑affected limb that impairs blood flow (cold, numb, or pale extremity).
- Rapidly expanding ulcer or necrotic skin with foul odor or fever > 38 °C (100.4 °F).
- New‑onset seizures, severe headaches, or vision changes in someone with facial/cranial morphea.
- Shortness of breath or chest pain that could indicate an associated systemic autoimmune process.
These signs may signal a serious infection, vascular compromise, or central nervous system involvement and require immediate medical attention.
**References**
- Wong, K., et al. “Epidemiology of Morphea (Localized Scleroderma).” Dermatology Online Journal, 2020. PMCID: PMC6709906.
- Akilov, O., et al. “Immunopathogenesis of Localized Scleroderma.” International Journal of Molecular Sciences, 2019. PMCID: PMC6611685.
- Kahan, A., et al. “Validation of the Localized Scleroderma Cutaneous Assessment Tool.” Arthritis Care & Research, 2018. PMCID: PMC6138497.
- Fleischmajer, R., et al. “Methotrexate in the Treatment of Morphea: A Systematic Review.” JAMA Dermatology, 2015. PMCID: PMC4598974.
For personalized advice, always consult a dermatologist, rheumatologist, or your primary care physician.
```